Competing risk regression models for epidemiologic data.
暂无分享,去创建一个
[1] J. Cornfield,et al. The estimation of the probability of developing a disease in the presence of competing risks. , 1957, American journal of public health and the nation's health.
[2] D. Cox,et al. THE ANALYSIS OF EXPONENTIALLY DISTRIBUTED LIFE-TIMES WITH Two TYPES OF FAILURE , 1959 .
[3] H. Seal. Studies in the history of probability and statistics , 1977 .
[4] C. L. Chiang,et al. Competing Risks and Conditional Probabilities , 1970 .
[5] V T Farewell,et al. The analysis of failure times in the presence of competing risks. , 1978, Biometrics.
[6] J. Kalbfleisch,et al. The Statistical Analysis of Failure Time Data , 1980 .
[7] Gregg E. Dinse,et al. A mixture model for the regression analysis of competing risks data , 1985 .
[8] B. Efron. The jackknife, the bootstrap, and other resampling plans , 1987 .
[9] R. Gray. A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk , 1988 .
[10] E L Korn,et al. Applications of crude incidence curves. , 1992, Statistics in medicine.
[11] M S Pepe,et al. Kaplan-Meier, marginal or conditional probability curves in summarizing competing risks failure time data? , 1993, Statistics in medicine.
[12] Jeffrey J. Gaynor,et al. On the Use of Cause-Specific Failure and Conditional Failure Probabilities: Examples from Clinical Oncology Data , 1993 .
[13] J. Klein,et al. Statistical Models Based On Counting Process , 1994 .
[14] M Lunn,et al. Applying Cox regression to competing risks. , 1995, Biometrics.
[15] D. Lin,et al. Non-parametric inference for cumulative incidence functions in competing risks studies. , 1997, Statistics in medicine.
[16] Joseph Feldman,et al. The Women's Interagency HIV Study , 1998 .
[17] D. Cotton. Do we still need a cohort study of women with HIV infection? , 1998, Epidemiology.
[18] M. Kenward,et al. Contribution to the discussion of the paper by Diggle, Tawn and Moyeed , 1998 .
[19] L. Kalish,et al. The Women's Interagency HIV Study. WIHS Collaborative Study Group. , 1998, Epidemiology.
[20] V. M. Shadle,et al. Self-reported antiretroviral therapy in injection drug users. , 1998, JAMA.
[21] Lee-Jen Wei,et al. Prediction of cumulative incidence function under the proportional hazards model. , 1998, Biometrics.
[22] Robert Gray,et al. A Proportional Hazards Model for the Subdistribution of a Competing Risk , 1999 .
[23] James M. Robins,et al. Causal Inference Without Counterfactuals: Comment , 2000 .
[24] Richard D Moore,et al. Detrimental Effects of Continued Illicit Drug Use on the Treatment of HIV‐1 Infection , 2001, Journal of acquired immune deficiency syndromes.
[25] D. Vlahov,et al. Time to initiating highly active antiretroviral therapy among HIV-infected injection drug users , 2001, AIDS.
[26] M. Crowder. Classical Competing Risks , 2001 .
[27] Susanne Rosthøj,et al. Competing risks as a multi-state model , 2002, Statistical methods in medical research.
[28] Anne M Johnson,et al. Changes over calendar time in the risk of specific first AIDS-defining events following HIV seroconversion, adjusting for competing risks. , 2002, International journal of epidemiology.
[29] Laurence L. George,et al. The Statistical Analysis of Failure Time Data , 2003, Technometrics.
[30] M. Zwahlen,et al. All cause mortality in the Swiss HIV cohort study from 1990 to 2001 in comparison with the Swiss population , 2004, AIDS.
[31] J. Satagopan,et al. A note on competing risks in survival data analysis , 2004, British Journal of Cancer.
[32] M. Young,et al. The Women's Interagency HIV Study: an Observational Cohort Brings Clinical Sciences to the Bench , 2005, Clinical Diagnostic Laboratory Immunology.
[33] G. Leung,et al. Methods for Estimating the Case Fatality Ratio for a Novel, Emerging Infectious Disease , 2005, American journal of epidemiology.
[34] Melania Pintilie,et al. Competing Risks: A Practical Perspective , 2006 .
[35] J. Castilla,et al. Delay in the initiation of HAART, poorer virological response, and higher mortality among HIV-infected injecting drug users in Spain. , 2006, AIDS research and human retroviruses.
[36] Haitao Chu,et al. Parametric survival analysis and taxonomy of hazard functions for the generalized gamma distribution , 2007, Statistics in medicine.
[37] Richard D Moore,et al. Risk of Non-AIDS-Related Mortality May Exceed Risk of AIDS-Related Mortality Among Individuals Enrolling Into Care With CD4+ Counts Greater Than 200 Cells/mm3 , 2007, Journal of acquired immune deficiency syndromes.
[38] M. Wolbers,et al. Comments on ‘Analysing and interpreting competing risk data’ (original article and author's reply) by Melania Pintilie, Statistics in Medicine 2007; 26:1360–1367; DOI: 10.1002/sim.2655 (original article) and Statistics in Medicine 2007; DOI: 10.1002/sim.2822 (author's reply) , 2007, Statistics in medicine.
[39] Martin Schumacher,et al. Misspecified regression model for the subdistribution hazard of a competing risk by Latouche A, Boisson V, Chevret S and Porcher R. Statistics in Medicine 2006; DOI: 10.2002/sim.2600 , 2007, Statistics in medicine.
[40] Mardge H. Cohen,et al. Mortality among participants in the Multicenter AIDS Cohort Study and the Women's Interagency HIV Study. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[41] Melania Pintilie,et al. Analysing and interpreting competing risk data , 2007, Statistics in medicine.
[42] J Beyersmann,et al. Comments on ‘Analysing and interpreting competing risk data’ by M. Pintilie, Statistics in Medicine 2006. DOI: 10.1002/sim.2655 , 2007, Statistics in medicine.
[43] A. D'Amico,et al. Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. , 2007, Journal of the National Cancer Institute.
[44] Martin Schumacher,et al. A competing risks analysis of bloodstream infection after stem‐cell transplantation using subdistribution hazards and cause‐specific hazards , 2007, Statistics in medicine.
[45] Bryan Lau,et al. Evaluating competing adverse and beneficial outcomes using a mixture model , 2008, Statistics in medicine.
[46] Mardge H. Cohen,et al. Patterns, predictors, and consequences of initial regimen type among HIV-infected women receiving highly active antiretroviral therapy. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[47] O. Kirk,et al. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration , 2008, The Lancet.
[48] J. Hanley. The Breslow estimator of the nonparametric baseline survivor function in Cox's regression model: some heuristics. , 2008, Epidemiology.
[49] Qian-Li Xue,et al. Life-space constriction, development of frailty, and the competing risk of mortality: the Women's Health And Aging Study I. , 2007, American journal of epidemiology.